BridgeBio Pharma, Inc.宣布,其针对ADH1(常染色体显性低尿钙性高钙血症1型)的在研药物Encaleret,在三期CALIBRATE临床试验中取得了积极结果。基于这一关键性研究的成功数据,公司已明确规划,预计将在2026年上半年向监管机构提交新药上市申请(NDA)。
此次试验结果的突破性进展,为ADH1这一罕见病患者群体带来了新的治疗希望。公司表示,将全力推进后续的申报准备工作,确保按时完成NDA提交。
BridgeBio Pharma, Inc.宣布,其针对ADH1(常染色体显性低尿钙性高钙血症1型)的在研药物Encaleret,在三期CALIBRATE临床试验中取得了积极结果。基于这一关键性研究的成功数据,公司已明确规划,预计将在2026年上半年向监管机构提交新药上市申请(NDA)。
此次试验结果的突破性进展,为ADH1这一罕见病患者群体带来了新的治疗希望。公司表示,将全力推进后续的申报准备工作,确保按时完成NDA提交。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.